A Divesture To Kick Up Valuation For Genzyme Drives U.S. Expansion For Japanese Diagnostic Firm
This article was originally published in The Pink Sheet Daily
Sale is the second of three units Genzyme said it would divest to generate shareholder value, but which is seen largely as a move to enhance valuation as it courts buyers.
You may also be interested in...
Sale of Genzyme Genetics for $925 million to LabCorp seen as enhancing the biotech's potential purchase value.
TOKYO - In an effort to expand its U.S. presence in preclinical services, Sekisui Chemical Co. says it plans to acquire Kansas-based contract research organization XenoTech in an undisclosed, all-cash transaction by the end of July
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.